Second-line chemotherapy in recurrent clear cell ovarian cancer: Results from the Multicenter Italian Trials in Ovarian cancer (MITO-9)

Oncology (Switzerland)

Volumn 86, Issue 5-6, 2014, Pages 351-358

  Esposito, Francesca ^a   Cecere, Sabrina Chiara ^a   Magazzino, Francescapaola ^b   Katsaros, Dionyssios ^d   Ottaiano, Alessandro ^a   Gadducci, Angiolo ^e   Pisano, Carmela ^a   Scalone, Simona ^f   Rabaiotti, Emanuela ^g   Salutari, Vanda ^h   Cormio, Gennaro ^b   Canuto, Emilie Marion ^d   Greggi, Stefano ^a   Savarese, Antonella ⁱ   Marinaccio, Marco ^c   Scollo, Paolo ^j   Santeufemia, Davide Adriano ^k   Sacco, Cosimo ^l   Facchini, Gaetano ^a   Pignata, Sandro ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c POLICLINICO   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF PISA   (Italy)

^f CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

ⁱ REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^j CANNIZZARO HOSPITAL   (Italy)

^k S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^l UNIVERSITY HOSPITAL OF UDINE   (Italy)

more..

Author keywords

Clear cell; Gemcitabine; Ovarian carcinoma; Second line chemotherapy

Indexed keywords

DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN; CARBOPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CLEAR CELL CARCINOMA; CLINICAL STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CLEAR CELL OVARIAN CARCINOMA; COHORT ANALYSIS; CONTROLLED STUDY; OVARY CARCINOMA; OVERALL SURVIVAL;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; ITALY; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84902301288     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000358730     Document Type: Article

References (38)

1. Schiller W: Mesonephroma ovarii. Am J Cancer 1939; 35: 1-21
2. Serov SF, Scully RE, Sobin LH: International histologic classification of tumors; in: Histologic Typing of Ovarian Tumors, No. 9. Geneva, World Health Organization, 1973
3. Seidman JD, Russell P, Kurman RJ: Surface epithelial tumors of the ovary; in Kurman RJ (ed): Blaustein's Pathology of the Female Genital Tract, ed 5. New York, Springer, 2002, p 791
4. Bamias A, Sotiropoulou M, Zagouri F, Trachana P, Sakellariou K, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA: Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: Cell type is the most useful prognostic factor. Eur J Cancer 2012; 48: 1476-1483
5. Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade- Lauraine E, Swart AM, Siddiqui N, Colombo N, Bookman MA, Pfisterer J, du Bois A; Gynecologic Cancer InterGroup: Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010; 20: 945-952
6. Behbakht K, Randall TC, Benjamin I, Morgan MA, King S, Rubin SC: Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998; 70: 255-258
7. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, Park RC: Long-term follow-up prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experiences. J Clin Oncol 1991; 9: 1138-1150
8. Goff BA, Sainz De la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, Nikrui N, Tamimi HK, Cain JM, Greer BE, Fuller AF Jr: Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60: 412-417
9. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum- based chemotherapy. Cancer 2000; 88: 2584-2589
10. Fujiwara K, Sakuragi N, Suzuki S, Yoshida N, Maehata K, Nishiya M, Koshida T, Sawai H, Aotani E, Kohno I: First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: Results of long-term follow-up. Gynecol Oncol 2003; 90: 637-643
11. Enomoto T, Kuragaki C, Yamasaki M: Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin?. Proc Am Soc Clin Oncol 2003; 22: 447
12. Pather S, Quinn MA: Clear-cell cancer of the ovary: Is it chemosensitive?. Int J Gynecol Cancer 2005; 15: 432-437
13. Aure JC, Hoeg K, Kolstad P: Clinical and histologic studies of ovarian carcinoma: Longterm follow-up of 990 cases. Obstet Gynecol 1971; 37: 1-9
14. Kennedy AW, Biscotti CV, Hart WR, Webster KD: Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989; 32: 342-349
15. Behbakht K, Randall TC, Benjamin I, Morgan MA, King S, Rubin SC: Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998; 70: 255-258
16. Jenison EL, Montag AG, Griffiths CT, Welch WR, Lavin PT, Greer J, Knapp RC: Clear cell adenocarcinoma of the ovary: A clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989; 32: 65-71
17. Crozier MA, Copeland LJ, Silva EG, Gershenson DM, Stringer CA: Clear cell carcinoma of the ovary: A study of 59 cases. Gynecol Oncol 1989; 35: 199-203
18. Ogawa S, Kaku T, Amada S, Kobayashi H, Hirakawa T, Ariyoshi K, Kamura T, Nakano H: Ovarian endometriosis associated with ovarian carcinoma: A clinicopathological and immunohistochemical study. Gynecol Oncol 2000; 77: 298-304
19. Silverberg SG: Ultrastructure and histogenesis of clear cell carcinoma of the ovary. Am J Obstet Gynecol 1973; 115: 394-400
20. Fukunaga M, Nomura K, Ishikawa E, Ushigome S: Ovarian atypical endometriosis: Its close association with malignant epithelial tumours. Histopathology 1997; 30: 249-255
21. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U: Carcinoma of the ovary: FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95(suppl 1):S161-S192
22. Mizuno M, Kikkawa F, Shibata K, Kajiyama H, Ino K, Kawai M, Nagasaka T, Nomura S: Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol 2006; 94: 138-143
23. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA: Advanced stage clear-cell epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2006; 102: 285-291
24. Ho CM, Huang YJ, Chen TC, Huang SH, Liu FS, Chang Chien CC, Yu MH, Mao TL, Wang TY, Hsieh CY: Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 2004; 94: 197-203
25. Utsunomiya H, Akahira J, Tanno S, Moriya T, Toyoshima M, Niikura H, Ito K, Morimura Y, Watanabe Y, Yaegashi N: Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: A multicenter trial. Int J Gynecol Cancer 2006; 16: 52-56
26. Ho CM, Chien TY, Shih BY, Huang SH: Evaluation of complete surgical staging with pelvic and para-Aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol 2003; 88: 394-399
27. Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Sugiyama T: Clear cell carcinoma of the ovary: A retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 2006; 94: 1369-1374
28. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM: Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 2007; 105: 404-408
29. Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GC: Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 2011; 21: 771-775
30. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, Reed H, Ellenson LH, Giordano TJ, Fearon ER, Hanash SM, Cho KR: Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor prognosis ovarian carcinomas. Cancer Res 2002; 62: 4722-4729
31. Magazzino F, Katsaros D, Ottaiano A, Gadducci A, Pisano C, Sorio R, Rabaiotti E, Scambia G, Cormio G, Scarampi L, Greggi S, Savarese A, Marinaccio M, Scollo P, Pignata S: Surgical and medical treatment of clear cell ovarian cancer: Results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study. Int J Gynecol Cancer 2011; 21: 1063-1070
32. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216
33. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, Mitchell H, Lambert HE: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14: 1545-1551
34. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C; ICON and AGO Collaborators: Paclitaxel plus platinum-based chemotherapy versus conventional platinumbased chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106
35. D'Agostino G, Amant F, Berteloot P, Scambia G, Vergote I: Phase II study of gemcitabine in recurrent platinum- And paclitaxel-resistant ovarian cancer. Gynecol Oncol 2003; 88: 266-269
36. Ferrandina G, Legge F, Mey V, Nannizzi S, Ricciardi S, Petrillo M, Corrado G, Scambia G: A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge. Cancer Chemother Pharmacol 2007; 60: 459-461
37. Bergman AM, Pinedo HM, Peters GJ: Determinants of resistance to 2',2' difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002; 5: 19-33
38. Sato J, Kimura T, Saito T, Anazawa T, Kenjo A, Sato Y, Tsuchiya T, Gotoh M: Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2011; 18: 700-711.